Cancer Metabolism Core

癌症代谢核心

• 批准号: 10707540
• 负责人: Pankaj Kumar Singh
• 金额: $ 9.37万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10707540
• 关键词: Address; Biological Assay; Carbon; Cell Line; Cells; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; Communication; Community Networks; Complex; Coupled; Data Analyses; Data Coordinating Center; Data Scientist; Dependence; Drug Kinetics; Ensure; Gas Chromatography; Genomic Library; Genus Hippocampus; Goals; Human; Information Dissemination; Infrastructure; Intercellular Fluid; Investigation; Kinetics; Label; Leadership; Libraries; Liquid Chromatography; Malignant neoplasm of pancreas; Mass Fragmentography; Mass Spectrum Analysis; Measures; Mediator; Medical center; Metabolic; Metabolic Pathway; Metabolism; Methods; Mus; Nebraska; Organoids; Oxygen Consumption; Pancreatic Ductal Adenocarcinoma; Patients; Pharmaceutical Preparations; Pharmacodynamics; Physiological; Publications; Publishing; Quality Control; Research Personnel; Resistance; Sampling; Services; Signal Transduction; Specimen; Stable Isotope Labeling; Statistical Methods; Stromal Neoplasm; Testing; Tissues; Training; Tumor Tissue; Universities; Work; cancer cell; chemotherapy; cost effective; design; effective therapy; exosome; experimental study; extracellular; follow-up; genetic manipulation; human tissue; improved; innovation; large scale data; lipidomics; member; metabolomics; neoplastic cell; novel; novel therapeutics; online resource; patient prognosis; programs; screening; stable isotope; tandem mass spectrometry; therapy resistant; three dimensional cell culture; tumor; tumor metabolism; whole genome

METABOLISM CORE Abstract The metabolism core of the proposed the UNMC Acquired Resistance to Therapy Network (ARTNet) Center for Pancreatic Cancer (ACPC) will study innovative, hypothesis-driven mechanisms of metabolic and signaling alterations that contribute to acquired therapy resistance in pancreatic ductal adenocarcinoma (PDAC). The core services provided by the metabolism core will be well integrated into all the three projects. The core will offer cost-effective metabolomics and data analysis support with appropriate quality controls for all projects by providing a centralized infrastructure and expertise in metabolomics, physiological assays, and metabolic dependency/vulnerability screens. The metabolism core will have three specific aims. The basic capabilities offered by the Core will include steady-state polar metabolomics and lipidomics (Specific Aim 1), Stable Isotope Resolved Metabolomics (SIRM) with kinetic flux analysis (Specific Aim 2), and Seahorse extracellular flux analyzer-based assays, fluorescent assays to investigate the metabolic state of cells, and identifying metabolic vulnerabilities (Specific Aim 3). The Metabolism Core will participate in the design and conduct of steady-state polar metabolomics, lipidomics, 13C-metabolite labeled kinetic flux analysis with cell lines, organoids, and exosomes. The core will also perform steady-state polar metabolomics and lipidomics for mouse and human tumor tissue specimens in all the projects. The core will also provide hands-on training, as needed, for the ACPC, other ARTNet centers, and other investigators. The core will also provide support for measuring drug concentrations and metabolism in the tissues and drug pharmacokinetics/ pharmacodynamics studies.

代谢的核心